Drug pricing is a hot button issue, including the pricing transparency battle, and it’s not going away anytime soon.
On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures, stating, “That policy very well could be an effective tool in halting the rising cost of prescription drugs. But no matter how vexing the problem of spiraling drug costs may be, HHS cannot do more than what Congress has authorized.” The Trump administration pushed back again, six weeks later, with an appeal to Judge Mehta’s ruling — so clearly, this battle is nowhere near over.
In a column penned for PharmaLive, Intouch EVP Wendy Blackburn lays out five options to get ahead of the ultimate ruling on this sticky situation, reminding us that if we don’t take action, action will be taken upon us.
Read the entire column here.